ASCO– tag –
-
FDA Approves Multiple Novel Cancer Therapeutics, Including Multi-Selective RAS(ON) Inhibitor Daraxonrasib and Next-Gen ADCs for Difficult-to-Treat Cancers
The ASCO Post USA Overview The U.S. FDA announced several groundbreaking cancer drug approvals on September 10, 2026, including daraxonrasib, a multi-selective RAS(ON) inhibitor, for metastatic pancreatic adenocarcinoma. Other approvals ... -
Ivonescimab Significantly Improves Overall Survival vs. Pembrolizumab in First-Line PD-L1 Positive Advanced NSCLC
The ASCO Post Unknown Overview Ivonescimab, a first-in-class PD-1/VEGF bispecific antibody, demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared to pembrolizumab as a first-line... -
First-in-Class Bispecific ADC BL-B01D1 Shows Antitumor Activity in Phase Ib Trial for Relapsed Extensive-Stage Small Cell Lung Cancer
ASCO Post USA Overview The first-in-class bispecific antibody-drug conjugate (ADC), izalontamab brengitecan (iza-bren, BL-B01D1), demonstrated promising antitumor activity in a Phase Ib study for relapsed extensive-stage small cell lung ... -
In Vivo CAR T-Cell Therapy KLN-1010 Achieves 100% MRD Negativity in Multiple Myeloma Phase 1 Trial, Presented at ASCO/EHA 2026
International Myeloma Foundation USA Overview At the 2026 ASCO and EHA meetings, groundbreaking results for KLN-1010, an in vivo CAR T-cell therapy eliminating the need for ex vivo T-cell harvest, were highlighted. The clinical trial in ... -
Ribo’s Divesiran (SLN124) Significantly Reduces Phlebotomy Frequency and Improves Patient QoL in Polycythemia Vera Phase IIa Trial
MPN Research Foundation Global Overview Divesiran (SLN124) from Ribo is an siRNA therapy designed to increase hepcidin levels, aiming to control erythrocyte overproduction in polycythemia vera (PV). Clinical trial results showed that pat... -
First-in-Class EGFR-HER3 Bispecific ADC Iza-Bren Achieves 48.1% ORR in Phase Ib for Extensive-Stage Small Cell Lung Cancer
ASCO Publications USA Overview Results from a Phase Ib study of Izalontamab Brengitecan (Iza-Bren), the first-in-class EGFR-HER3 bispecific antibody-drug conjugate (ADC) for extensive-stage small cell lung cancer (SCLC), have been announ... -
Jordan Advances Global CAR-T Access with High-Efficiency Point-of-Care Manufacturing Using CliniMACS Prodigy
ASCO Publications Jordan Overview In a significant step towards democratizing advanced cell therapies, point-of-care manufacturing of anti-CD19.1 CAR-T cells using the Miltenyi CliniMACS Prodigy system was successfully demonstrated in Jo... -
ASCO Podcast: Optimizing Frontline ADCs as They Shift to Earlier Cancer Treatment Stages
ASCO Publications USA Overview An ASCO Publications podcast discusses the rapid integration of antibody-drug conjugates (ADCs) into frontline advanced and curative-intent perioperative settings for cancer treatment. Experts emphasize tha... -
Antibody-Drug Conjugates (ADCs) Show Promise for Epithelioid Hemangioendothelioma (EHE) Treatment: Highlighted at ASCO 2026
EHE Foundation USA Overview Antibody-drug conjugates (ADCs) are gaining significant attention as a promising emerging strategy for treating epithelioid hemangioendothelioma (EHE), a rare and challenging cancer. ADCs deliver potent anti-c... -
BMS Molecular Glue Mezigdomide Combination Therapy Transforms Oncology: Achieves 52% Reduction in Progression or Death Risk in Phase 3 Multiple Myeloma Trial
PMLiVE Unknown Overview Targeted protein degraders (TPDs), specifically PROTACs and molecular glues, are rapidly advancing in oncology. At ASCO, Bristol Myers Squibb (BMS) announced Phase 3 results showing their molecular glue, Mezigdomi...
12